Ricevi le ultime notizie sulle azioni Seres Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MCRB

Ultime notizie per

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

Earnings

Press Releases

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

News

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Health Care

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

General

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

MCRB

SANA

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

C4 Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

Forte Biosciences

Genfit

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Comments

Seres Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO